Anixa Biosciences, Inc.
- Open
- 3.51
- Day high
- 3.56
- Day low
- 3.34
- Prev close
- 3.56
- Volume
- 132K
- Mkt cap
- $116M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 8.0
- P/S
- —
- Yield
- —
- Per share
- —
- ▲Insiders net buying $182K over the last 3 months (9 open-market buys, 0 sales)
- ◆Cluster buying — multiple insiders bought within days
- 🏛Institutions mixed (13F)
Anixa Biosciences, Inc. (ANIX) is a Healthcare company listed on NASDAQ. The stock is up 12% over the past year. Over the trailing 3 months, insiders filed 9 open-market buys and 0 sales (SEC Form 4).
Anixa Biosciences, Inc. (ANIX) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
ANIX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jun 10, 2026 | $-0.10 | $-0.07 | +30.0% | — | — |
| Mar 9, 2026 | $-0.09 | $-0.08 | +10.2% | — | — |
| Sep 10, 2025 | $-0.10 | $-0.07 | +30.0% | — | — |
| May 28, 2025 | $-0.10 | $-0.09 | +10.0% | — | — |
| Mar 11, 2025 | $-0.10 | $-0.10 | +0.0% | — | — |
| Sep 6, 2024 | $-0.11 | $-0.10 | +9.1% | — | — |
| Jun 4, 2024 | $-0.11 | $-0.10 | +9.1% | — | — |
| Mar 12, 2024 | $-0.09 | $-0.10 | -11.1% | — | — |
| Sep 6, 2023 | $-0.09 | $-0.08 | +11.1% | — | — |
| Jun 14, 2023 | $-0.11 | $-0.07 | +36.4% | $210000 | — |
| Mar 16, 2023 | $-0.16 | $-0.08 | +50.0% | — | — |
| Sep 9, 2022 | $-0.13 | $-0.09 | +30.8% | — | — |
ANIX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 29, 2026 | Baskies Arnold Mdirector | Tax | 5,428 | $3.46 |
| Jul 29, 2026 | Baskies Arnold Mdirector | Option | 6,000 | $3.13 |
| Jul 28, 2026 | KUMAR AMITdirector, officer: Chief Executive Officer | Buy | 5,000 | $3.44 |
| Jul 27, 2026 | KUMAR AMITdirector, officer: Chief Executive Officer | Buy | 3,188 | $3.37 |
| Jul 27, 2026 | KUMAR AMITdirector, officer: Chief Executive Officer | Buy | 3,000 | $3.73 |
| Jul 21, 2026 | KUMAR AMITdirector, officer: Chief Executive Officer | Buy | 5,000 | $3.46 |
| Jul 20, 2026 | Titterton Lewis H jrdirector | Buy | 12,000 | $3.47 |
| Jul 16, 2026 | Titterton Lewis H jrdirector | Buy | 2,797 | $3.28 |
| Jul 13, 2026 | KUMAR AMITdirector, officer: Chief Executive Officer | Buy | 5,000 | $3.04 |
| Jun 17, 2026 | Titterton Lewis H jrdirector | Buy | 2,836 | $2.64 |
| Jun 16, 2026 | KUMAR AMITdirector, officer: Chief Executive Officer | Buy | 21,000 | $2.50 |
| Jan 29, 2026 | Baskies Arnold Mdirector | Buy | 10,000 | $3.04 |
| Jan 6, 2026 | Titterton Lewis H jrdirector | Grant | 25,000 | $3.18 |
| Jan 6, 2026 | Gottschalk Emilydirector | Grant | 25,000 | $3.18 |
| Jan 6, 2026 | Baskies Arnold Mdirector | Grant | 25,000 | $3.18 |
Source: ANIX SEC Form 4 filings, latest Jul 29, 2026. For informational purposes only — not investment advice.
See the full ANIX insider & 13F page →Anixa Biosciences, Inc. company profile
Overview
Anixa Biosciences, Inc. (NASDAQ:ANIX) is a biotechnology company founded in 1982 and originally incorporated as ITUS Corporation before changing its name in October 2018. Based in San Jose, California, the company has transitioned from its original business focus to become a clinical-stage biotechnology firm developing innovative therapies and vaccines for oncology and infectious diseases. The company went public in 1983 and has since evolved into a research-focused organization targeting critical unmet medical needs through advanced immunotherapy and vaccine technologies.
Business
Anixa Biosciences operates in the biotechnology sector, specifically focusing on developing treatments for cancer and infectious diseases. The company's work centers around two primary therapeutic areas that represent significant unmet medical needs. The company's oncology programs form the core of its business, representing the majority of its research and development efforts. These include the development of chimeric endocrine receptor T-cell (CER-T) technology, which is a novel variation of chimeric antigen receptor T-cell (CAR-T) therapy specifically designed to treat ovarian cancer. CAR-T therapy is an advanced form of immunotherapy that involves genetically modifying a patient's own T-cells to better recognize and attack cancer cells. Anixa's CER-T approach represents an innovative twist on this established technology, targeting hormone receptors that are commonly found on certain cancer cells. The company is also developing cancer vaccines, including a preventative vaccine against ovarian cancer and a therapeutic vaccine targeting triple-negative breast cancer. Cancer vaccines work by training the immune system to recognize and attack specific proteins or antigens that are associated with cancer cells, potentially preventing cancer development or helping treat existing cancers. In addition to oncology, Anixa has infectious disease programs, primarily focused on developing antiviral drug candidates for COVID-19 treatment. These drugs are designed to inhibit specific protein functions of the SARS-CoV-2 virus, potentially preventing viral replication and reducing disease severity. The company collaborates with MolGenie GmbH, a German biotechnology company, on this antiviral research. The company also develops broader immunotherapy drugs against various cancers, leveraging the body's immune system to fight malignancies. Given the early-stage nature of most programs and lack of detailed revenue breakdowns in available financial data, specific revenue contributions from each segment are not readily available, though oncology appears to be the primary focus based on the company's strategic direction.
Revenue model
Anixa Biosciences operates as a clinical-stage biotechnology company with no current product revenue, as evidenced by its recent financial statements showing zero revenue in most quarters (except for $210,000 in fiscal 2023, likely from licensing or collaboration agreements). The company's business model is typical of early-stage biotech firms, relying primarily on research and development funding rather than product sales. The company's future revenue model will likely center around several key mechanisms once its therapies advance through clinical trials and regulatory approval. Product licensing and partnerships represent a primary revenue opportunity, where Anixa could license its CER-T technology, cancer vaccines, or antiviral compounds to larger pharmaceutical companies in exchange for upfront payments, milestone payments, and royalties on future sales. The collaboration with MolGenie GmbH exemplifies this approach. Direct product sales would become relevant if Anixa successfully brings its therapies to market, though this is typically years away for clinical-stage companies. Cancer immunotherapies and vaccines, if successful, can command premium pricing due to their life-saving potential and the high unmet medical need in oncology. Several factors could significantly impact the company's margins and financial performance. Regulatory approval timelines represent a major variable, as longer development periods increase costs and delay revenue generation. Clinical trial success rates are crucial, since failed trials can eliminate entire revenue streams while successful results can dramatically increase asset values. Competition from larger pharmaceutical companies developing similar CAR-T therapies or cancer vaccines could pressure pricing and market share. Healthcare reimbursement policies will significantly affect the commercial viability of any approved products, as insurance coverage determines patient access and pricing power. Manufacturing costs for complex therapies like CAR-T treatments are substantial and could impact margins, while intellectual property protection will determine the company's ability to maintain competitive advantages and pricing power in its target markets.
Competitive moat
Anixa Biosciences operates in a highly competitive biotechnology landscape where sustainable competitive advantages are challenging to establish and maintain. The company's primary potential moat lies in its intellectual property portfolio surrounding its CER-T technology and cancer vaccine approaches. If these technologies prove clinically superior and can be protected through robust patent portfolios, they could provide temporary competitive advantages. However, the company's moat appears relatively narrow and unproven at this stage. The biotechnology industry is characterized by rapid innovation, substantial capital requirements, and high failure rates, making it difficult for smaller companies to maintain long-term competitive positions. Larger pharmaceutical companies possess significantly greater resources for research and development, clinical trials, regulatory navigation, and commercialization, potentially allowing them to develop competing therapies or acquire promising smaller companies. The regulatory approval process itself provides some temporary protection, as successfully navigating FDA approval creates barriers for competitors. However, this protection is limited by patent expiration timelines and the constant threat of next-generation therapies that could render current approaches obsolete. Potential disruption comes from multiple sources. Large pharmaceutical companies like Novartis, Gilead, and Bristol Myers Squibb already have approved CAR-T therapies and substantial resources to develop competing technologies. Academic institutions and other biotechnology companies are actively researching similar immunotherapy approaches. Additionally, entirely different therapeutic modalities, such as advanced precision medicine approaches or novel drug delivery systems, could potentially address the same medical needs more effectively. The company's collaboration strategy with partners like MolGenie provides access to additional expertise and resources but also means sharing potential upside and control over key programs. Overall, while Anixa's specialized focus and innovative approaches provide some differentiation, the company lacks the scale, resources, and proven track record that would constitute a strong competitive moat in the biotechnology sector.
Risks & safety
Anixa Biosciences presents a mixed margin of safety profile typical of early-stage biotechnology companies, with strong liquidity but significant operational risks. **Cash Position and Burn Rate:** - Current cash and short-term investments of $1.05 million as of Q1 2025, down from $1.27 million in Q4 2024 - Quarterly cash burn averaging approximately $2.9 million based on operating cash flow - Current cash runway appears limited to less than one quarter at current burn rates - Strong current ratio of 9.35x indicates good short-term liquidity relative to immediate obligations **Debt and Solvency:** - Minimal debt with debt-to-equity ratio of only 1.3% - Total liabilities of $2.2 million against $18.9 million in total assets - No apparent solvency risk in the near term due to low debt levels - However, the company will likely need additional funding within the next few quarters **Valuation Metrics:** - Trading at 5.2x book value, which is elevated for a loss-making company - Negative P/E ratio of -7.3x due to losses - Enterprise value to EBITDA of -6.8x (negative due to losses) - Graham net-net ratio of 0.47, indicating the stock trades below liquidation value **Other Considerations:** - Zero revenue generation creates complete dependence on external funding - Clinical-stage assets carry high binary risk (success/failure outcomes) - Strong balance sheet provides some downside protection but limited cash runway creates urgency for additional financing or partnerships
Recent development
Based on the available financial data, Anixa Biosciences has undergone significant strategic transformation over recent years, though detailed earnings call transcripts are not available to provide specific operational updates. The most notable development was the company's name change from ITUS Corporation to Anixa Biosciences in October 2018, reflecting a complete strategic pivot from its original business model to focus entirely on biotechnology and life sciences. The company's financial trajectory shows a dramatic shift in business focus, evidenced by the unusual revenue figure of $2.47 billion in fiscal 2022, which likely represents a one-time transaction or asset sale related to the disposal of legacy business operations. This was followed by minimal revenue of $210,000 in fiscal 2023 and zero revenue in fiscal 2024, confirming the transition to a pure-play biotechnology research and development model. Research and development intensification is evident from the consistent operational losses ranging from $9.9 million to $12.7 million annually over the past few years, indicating substantial investment in clinical programs. The company has maintained a strong balance sheet throughout this transition, with current assets exceeding $18-25 million and minimal debt obligations. The establishment of strategic partnerships represents another key development, particularly the collaboration agreement with MolGenie GmbH for COVID-19 antiviral drug development. This partnership approach allows Anixa to leverage external expertise and potentially share development costs and risks while maintaining access to promising therapeutic programs. The company's focus on innovative immunotherapy approaches has crystallized around its CER-T technology platform and cancer vaccine programs, representing a concentrated bet on next-generation cancer treatment modalities. The consistent cash burn and research focus suggest ongoing clinical development activities, though specific program advancement details are not available from the financial data alone.
ANIX company profile · for informational purposes only — not investment advice.
Track ANIX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free